Icotrokinra (Icotyde)

Psoriasis vulgaris is a chronic inflammatory skin disease that classically presents with well-demarcated, red plaques with silvery scale, commonly involving the scalp, elbows, knees, and presacral region, though any area of skin may be involved, including the palms, soles, nails, and genitalia. Icotrokinra(Icotyde) is an oral interleukin-23 (IL-23) receptor antagonist that blocks the chronic inflammatory cascade and in turn reduces the severity of symptoms. This review outlines the pharmacological profile, clinical efficacy, and safety data of Icotrokinra, including results from a pivotal randomized, placebo-controlled trial that demonstrated significant improvement in Psoriasis Area and Severity Index and IGA scores from baseline in patients with moderate to severe plaque psoriasis. The review also discusses its pharmacokinetics, adverse event profile, and usage considerations in specific populations. Icotrokinra represents a first in class oral IL23-R antagonist peptide treatment option for managing moderate to severe plaque psoriasis.